Pacira BioSciences, Inc. (PCRX) shareholders
Close on Nov 17, 2026Market cap $1.45BP/E 104.2Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| BlackRock, Inc. | 7,017,119 | 15.20% | 13G (passive) amendment | Mar 31, 2025 |
| Joe M. Thomson Joint filing with Pacer Advisors, Inc. (6.93%), Pacer US Small Cap Cash Cows ETF (6.92%) | 3,262,837 | 6.93% | 13G (passive) | Dec 31, 2024 |
| Pedro Escudero Joint filing with Doma Perpetual Capital Management LLC (6.90%), Doma1 LLC (6.90%) | 2,936,794 | 7.30% | 13D (active) amendment | Mar 11, 2026 |
| Doma2 LLC Joint filing with Doma Perpetual Capital Management LLC (6.83%), DOMA Perpetual LO Equity Master Fund LP (6.83%) and 2 more | 2,936,794 | 6.83% | 13D (active) amendment | Nov 6, 2025 |
| Vanguard Portfolio Management | 2,585,964 | 6.38% | 13G (passive) | Mar 31, 2026 |
| Renaissance Technologies LLC Joint filing with Renaissance Technologies Holdings Corporation (5.34%) | 2,395,601 | 5.34% | 13G (passive) | Apr 8, 2025 |
| Israel A. Englander Joint filing with Millennium Management LLC (5.10%), Millennium Group Management LLC (5.10%) | 2,338,369 | 5.10% | 13G (passive) | Jan 10, 2025 |
| Dimensional Fund Advisors LP | 2,060,597 | 5.10% | 13G (passive) | Mar 31, 2026 |
| State Street Corporation | 2,059,977 | 5.20% | 13G (passive) | Jun 30, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of PCRX | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 6,705,809 | 16.82% | $170.13M | −29,534 | 0.00% |
| Doma Perpetual Capital Management LLC | 2,777,794 | 6.97% | $70.47M | – | 16.36% |
| Vanguard Portfolio Management LLC | 2,406,238 | 6.04% | $61.05M | −95,048 | 0.00% |
| Dimensional Fund Advisors LP | 2,103,245 | 5.28% | $53.36M | +42,648 | 0.01% |
| State Street Corp | 2,059,977 | 5.17% | $52.26M | +140,367 | 0.00% |
| D. E. Shaw & Co., Inc. | 1,950,332 | 4.89% | $49.48M | −32,392 | 0.02% |
| Renaissance Technologies LLC | 1,733,801 | 4.35% | $43.99M | −91,700 | 0.06% |
| Vanguard Capital Management LLC | 1,691,571 | 4.24% | $42.92M | −92,478 | 0.00% |
| Goldman Sachs Group Inc | 1,527,129 | 3.83% | $38.74M | −42,787 | 0.00% |
| Geode Capital Management, LLC | 1,158,693 | 2.91% | $29.40M | +14,873 | 0.00% |
| Morgan Stanley | 1,144,654 | 2.87% | $29.04M | −247,894 | 0.00% |
| American Century Companies Inc | 1,018,093 | 2.55% | $25.83M | +180,530 | 0.01% |
| UBS Group AG | 920,217 | 2.31% | $23.35M | +358,177 | 0.00% |
| Impax Asset Management Group plc | 750,027 | 1.88% | $19.03M | – | 0.12% |
| Two Sigma Investments, LP | 724,604 | 1.82% | $18.38M | +197,753 | 0.01% |
| Charles Schwab Investment Management Inc | 690,786 | 1.73% | $17.53M | −41,256 | 0.00% |
| Gagnon Securities LLC | 608,617 | 1.53% | $15.44M | −8,893 | 2.98% |
| Lsv Asset Management | 608,376 | 1.53% | $15.43M | +91,276 | 0.03% |
| Wellington Management Group Llp | 563,458 | 1.41% | $14.29M | +85,075 | 0.00% |
| Northern Trust Corp | 526,782 | 1.32% | $13.36M | +7,370 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 253 | 44M | 100.0% | 38 / 82 | 84 / 24 | 3M | 3M |
| Q1 2026 | 242 | 44M | 100.0% | 29 / 90 | 85 / 43 | 7M | 6M |
| Q4 2025 | 261 | 47M | 100.0% | 49 / 87 | 92 / 24 | 5M | 6M |
| Q3 2025 | 239 | 48M | 100.0% | 37 / 66 | 96 / 30 | 5M | 7M |
| Q2 2025 | 233 | 51M | 100.0% | 31 / 84 | 77 / 32 | 6M | 6M |
| Q1 2025 | 235 | 51M | 100.0% | 35 / 84 | 77 / 31 | 10M | 9M |
| Q4 2024 | 233 | 50M | 100.0% | 36 / 77 | 80 / 40 | 8M | 10M |
| Q3 2024 | 239 | 52M | 100.0% | 47 / 88 | 68 / 88 | 24M | 16M |
| Q2 2024 | 282 | 53M | 100.0% | 51 / 106 | 76 / 38 | 8M | 6M |
| Q1 2024 | 271 | 51M | 100.0% | 38 / 99 | 83 / 28 | 6M | 4M |
| Q4 2023 | 261 | 49M | 100.0% | 41 / 88 | 91 / 38 | 7M | 5M |
| Q3 2023 | 261 | 47M | 100.0% | 41 / 96 | 87 / 38 | 5M | 5M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
291 funds held PCRX in Q2 2026, 60% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of PCRX | Value | % of fund | As of |
|---|---|---|---|---|---|
| iShares Core S&P Small-Cap ETF | 2,371,127 | 5.95% | $60.16M | 0.05% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 1,198,792 | 3.01% | $30.41M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 1,033,788 | 2.59% | $26.23M | 0.03% | Jun 30, 2026 |
| Vanguard Small-Cap Index Fund | 856,213 | 2.15% | $21.72M | 0.01% | Jun 30, 2026 |
| Avantis U.S. Small Cap Value ETF | 762,506 | 1.91% | $17.71M | 0.07% | May 31, 2026 |
| Impax Small Cap Fund | 750,027 | 1.88% | $19.03M | 2.00% | Jun 30, 2026 |
| U.S. Small Cap Value Portfolio | 570,177 | 1.43% | $15.06M | 0.08% | Jul 31, 2026 |
| Vanguard Small-Cap Value Index Fund | 542,876 | 1.36% | $13.77M | 0.02% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 453,754 | 1.14% | $11.51M | 0.01% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 432,505 | 1.09% | $11.42M | 0.03% | Jul 31, 2026 |
| State Street(R) SPDR(R) Portfolio S&P 600(TM) Small Cap ETF | 360,632 | 0.90% | $9.15M | 0.05% | Jun 30, 2026 |
| iShares S&P Small-Cap 600 Growth ETF | 351,941 | 0.88% | $8.93M | 0.11% | Jun 30, 2026 |
| DWS Small Cap Core Fund | 349,906 | 0.88% | $8.88M | 0.77% | Jun 30, 2026 |
| iShares Russell 2000 Value ETF | 340,170 | 0.85% | $8.63M | 0.06% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Pharmaceuticals ETF | 279,152 | 0.70% | $7.08M | 1.65% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Frank D. Lee | Chief Executive Officer, Director | 0 | – | Nov 17, 2026 |
| Jonathan Slonin | Chief Medical Officer | 0 | – | Nov 17, 2026 |
| Shawn Cross | Chief Financial Officer | 0 | – | Nov 17, 2026 |
| Kristen Williams | Chief Administrative Officer | 0 | – | Nov 17, 2026 |
| Brendan Teehan | Chief Commercial Officer | 0 | – | Nov 17, 2026 |
| Lauren Riker | Senior Vice President, Finance | 0 | – | Nov 17, 2026 |
| Daryl Gaugler | Chief Operating Officer | 115,443 | 0.29% | Jan 6, 2025 |
| Marcelo Bigal | Director | 0 | – | Nov 17, 2026 |
| Michael J. Yang | Director | 0 | – | Nov 17, 2026 |
| Thomas G. Wiggans | Director | – | – | Nov 17, 2026 |
| Laura Brege | Director | 0 | – | Nov 17, 2026 |
| Mark Froimson | Director | 0 | – | Nov 17, 2026 |
| Christopher Christie | Director | 0 | – | Nov 17, 2026 |
| Samit Hirawat | Director | 0 | – | Nov 17, 2026 |
| Alethia Young | Director | 0 | – | Nov 17, 2026 |
| Mark A. Kronenfeld | Director | 31,065 | 0.08% | Mar 19, 2026 |
| Abraham Ceesay | Director | 9,039 | 0.02% | Sep 8, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Frank D. Lee Chief Executive Officer, Director | Nov 17, 2026 | Returned to company | −660,830.841 | $36.50 | $24.12M | 0 |
| Alethia Young Director | Nov 17, 2026 | Returned to company | −17,798 | $36.50 | $649.63K | 0 |
| Samit Hirawat Director | Nov 17, 2026 | Returned to company | −6,405 | $36.50 | $233.78K | 0 |
| Michael J. Yang Director | Nov 17, 2026 | Returned to company | −6,405 | $36.50 | $233.78K | 0 |
| Michael J. Yang Director | Nov 17, 2026 | Tender of shares | −13,393 | $36.50 | $488.84K | 6,405 |
| Kristen Williams Chief Administrative Officer | Nov 17, 2026 | Returned to company | −167,062 | $36.50 | $6.10M | 0 |
| Brendan Teehan Chief Commercial Officer | Nov 17, 2026 | Returned to company | −100,934.268 | $36.50 | $3.68M | 0 |
| Christopher Christie Director | Nov 17, 2026 | Returned to company | −6,405 | $36.50 | $233.78K | 0 |
| Christopher Christie Director | Nov 17, 2026 | Tender of shares | −16,654 | $36.50 | $607.87K | 6,405 |
| Shawn Cross Chief Financial Officer | Nov 17, 2026 | Returned to company | −86,591 | $36.50 | $3.16M | 0 |
| Shawn Cross Chief Financial Officer | Nov 17, 2026 | Tender of shares | −9,210 | $36.50 | $336.17K | 86,591 |
| Mark Froimson Director | Nov 17, 2026 | Returned to company | −6,405 | $36.50 | $233.78K | 0 |
| Mark Froimson Director | Nov 17, 2026 | Tender of shares | −20,136 | $36.50 | $734.96K | 6,405 |
| Marcelo Bigal Director | Nov 17, 2026 | Returned to company | −6,405 | $36.50 | $233.78K | 0 |
| Marcelo Bigal Director | Nov 17, 2026 | Tender of shares | −11,393 | $36.50 | $415.84K | 6,405 |
| Lauren Riker Senior Vice President, Finance | Nov 17, 2026 | Returned to company | −55,403 | $36.50 | $2.02M | 0 |
| Lauren Riker Senior Vice President, Finance | Nov 17, 2026 | Tender of shares | −6,881.242 | $36.50 | $251.17K | 55,403 |
| Laura Brege Director | Nov 17, 2026 | Returned to company | −6,405 | $36.50 | $233.78K | 0 |
| Laura Brege Director | Nov 17, 2026 | Tender of shares | −23,715 | $36.50 | $865.60K | 6,405 |
| Jonathan Slonin Chief Medical Officer | Nov 17, 2026 | Returned to company | −216,729.67 | $36.50 | $7.91M | 0 |
| Shawn Cross Chief Financial Officer | Oct 30, 2026 | Tax withholding | −9,540 | $36.39 | $347.16K | 95,801 |
| Lauren Riker Senior Vice President, Finance | Oct 8, 2026 | Sale(10b5-1 plan) | −6,000 | $36.32 | $217.92K | 62,284 |
| Lauren Riker Senior Vice President, Finance | Oct 8, 2026 | Option exercise | +6,000 | $32.35 | $194.10K | 68,284 |
| Jonathan Slonin Chief Medical Officer | Aug 17, 2026 | Sale(10b5-1 plan) | −3,040 | $23.23 | $70.62K | 216,384 |
| Lauren Riker Senior Vice President, Finance | Jun 11, 2026 | Sale(10b5-1 plan) | −6,115 | $23.50 | $143.70K | 62,284 |
| Christopher Christie Director | Jun 10, 2026 | Award | +6,405 | – | – | 23,059 |
| Michael J. Yang Director | Jun 10, 2026 | Award | +6,405 | – | – | 19,798 |
| Samit Hirawat Director | Jun 10, 2026 | Award | +6,405 | – | – | 6,405 |
| Laura Brege Director | Jun 10, 2026 | Award | +6,405 | – | – | 30,120 |
| Alethia Young Director | Jun 10, 2026 | Award | +6,405 | – | – | 17,798 |
| Mark Froimson Director | Jun 10, 2026 | Award | +6,405 | – | – | 26,541 |
| Marcelo Bigal Director | Jun 10, 2026 | Award | +6,405 | – | – | 17,798 |
| Kristen Williams Chief Administrative Officer | Jun 4, 2026 | Sale(10b5-1 plan) | −10,259 | $22.27 | $228.47K | 167,062 |
| Kristen Williams Chief Administrative Officer | Jun 3, 2026 | Tax withholding | −8,528 | $22.32 | $190.34K | 177,321 |
| Jonathan Slonin Chief Medical Officer | Jun 3, 2026 | Tax withholding | −4,728 | $22.32 | $105.53K | 218,912 |
| Lauren Riker Senior Vice President, Finance | Jun 3, 2026 | Tax withholding | −3,187 | $22.32 | $71.13K | 68,399 |
| Shawn Cross Chief Financial Officer | Apr 23, 2026 | Sale(10b5-1 plan) | −12,941 | $25.16 | $325.60K | 105,341 |
| Shawn Cross Chief Financial Officer | Apr 23, 2026 | Option exercise | +12,941 | $16.45 | $212.88K | 118,282 |
| Shawn Cross Chief Financial Officer | Apr 22, 2026 | Sale(10b5-1 plan) | −1,500 | $25.01 | $37.52K | 105,341 |
| Shawn Cross Chief Financial Officer | Apr 22, 2026 | Option exercise | +1,500 | $16.45 | $24.68K | 106,841 |
| Shawn Cross Chief Financial Officer | Apr 21, 2026 | Sale(10b5-1 plan) | −2,845 | $25.01 | $71.15K | 105,341 |
| Shawn Cross Chief Financial Officer | Apr 21, 2026 | Option exercise | +2,845 | $16.45 | $46.80K | 108,186 |
| Shawn Cross Chief Financial Officer | Apr 20, 2026 | Option exercise | +7,714 | $16.45 | $126.90K | 113,055 |
| Shawn Cross Chief Financial Officer | Apr 20, 2026 | Sale(10b5-1 plan) | −7,714 | $25.14 | $193.93K | 105,341 |
| Mark Froimson Director | Mar 17, 2026 | Sale | −500 | $21.81 | $10.91K | 20,136 |
| Jonathan Slonin Chief Medical Officer | Mar 17, 2026 | Sale(10b5-1 plan) | −3,261 | $22.82 | $74.42K | 223,640 |
| Shawn Cross Chief Financial Officer | Feb 11, 2026 | Award | +49,091 | – | – | 105,341 |
| Jonathan Slonin Chief Medical Officer | Feb 11, 2026 | Award | +54,546 | – | – | 226,901 |
| Brendan Teehan Chief Commercial Officer | Feb 11, 2026 | Award | +51,714 | – | – | 100,934 |
| Frank D. Lee Chief Executive Officer, Director | Feb 11, 2026 | Award | +261,818 | – | – | 660,831 |
| Kristen Williams Chief Administrative Officer | Feb 11, 2026 | Award | +54,546 | – | – | 185,849 |
| Lauren Riker Senior Vice President, Finance | Feb 11, 2026 | Award | +19,273 | – | – | 71,586 |
| Kristen Williams Chief Administrative Officer | Feb 2, 2026 | Sale(10b5-1 plan) | −13,137 | $20.53 | $269.70K | 131,303 |
| Lauren Riker Senior Vice President, Finance | Feb 2, 2026 | Sale(10b5-1 plan) | −4,000 | $20.81 | $83.24K | 52,313 |
| Kristen Williams Chief Administrative Officer | Jan 30, 2026 | Tax withholding | −17,134 | $20.54 | $351.93K | 144,440 |
| Frank D. Lee Chief Executive Officer, Director | Jan 30, 2026 | Tax withholding | −41,488 | $20.54 | $852.16K | 399,013 |
| Lauren Riker Senior Vice President, Finance | Jan 30, 2026 | Tax withholding | −2,751 | $20.54 | $56.51K | 56,313 |
| Jonathan Slonin Chief Medical Officer | Jan 30, 2026 | Tax withholding | −6,168 | $20.54 | $126.69K | 172,355 |
| Brendan Teehan Chief Commercial Officer | Jan 30, 2026 | Tax withholding | −5,182 | $20.54 | $106.44K | 49,220 |
| Lauren Riker Senior Vice President, Finance | Jan 5, 2026 | Sale(10b5-1 plan) | −1,416 | $24.24 | $34.32K | 59,064 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Pacira BioSciences's stock actually held short. Settlement fails (shares not delivered on time) peaked at 16,029 shares on Oct 9, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Lauren Riker Officer | Oct 8, 2026 | 6,000 | $217.92K | Oct 8, 2026 | Stock Option Exercise |
| Jonathan Slonin Officer | Aug 17, 2026 | 3,040 | $70.62K | Aug 17, 2026 | ESPP Purchase |
| Abraham Ceesay Director | Jun 12, 2026 | 9,039 | $210.37K | Jun 12, 2026 | Restricted Stock Vesting |
| Lauren Riker Officer | Jun 11, 2026 | 6,115 | $143.70K | Jun 11, 2026 | Restricted Stock Vesting |
| Kristen Williams Officer | Jun 4, 2026 | 10,259 | $228.47K | Jun 4, 2026 | Restricted Stock Vesting |
| Shawn Cross Officer | Apr 23, 2026 | 12,941 | $325.58K | Apr 23, 2026 | Options Granted - 11/04/2024 |
| Shawn Cross Officer | Apr 22, 2026 | 1,500 | $37.52K | Apr 22, 2026 | Option Granted - 11/04/2024 |
| Shawn Cross Officer | Apr 21, 2026 | 2,845 | $71.15K | Apr 21, 2026 | Option Granted - 11/04/2024 |
| Shawn Cross Officer | Apr 20, 2026 | 7,714 | $193.91K | Apr 20, 2026 | Option Granted 11/04/2024 |
| Jonathan Slonin Officer | Mar 17, 2026 | 3,261 | $74.42K | Mar 17, 2026 | ESPP Purchase |
| Mark Froimson Director | Mar 17, 2026 | 500 | $10.91K | Mar 17, 2026 | Restricted Stock Vesting |
| Kristen Williams Officer | Feb 2, 2026 | 13,137 | $269.70K | Feb 2, 2026 | Restricted Stock Vesting |
| Lauren Riker Officer | Feb 2, 2026 | 4,000 | $84.22K | Feb 2, 2026 | Restricted Stock Vesting |
| Lauren Riker Officer | Jan 5, 2026 | 1,416 | $34.32K | Jan 5, 2026 | ESPP Purchase |
| Shawn Cross Officer | Dec 10, 2025 | 9,104 | $228.91K | Dec 10, 2025 | Option Granted 11/04/2024 |
Congress trades
8 trades in Pacira BioSciences reported by 1 member of the House
| Member | Type | Traded | Amount | Filed |
|---|---|---|---|---|
| Tom Malinowski NJ07 | Bought | May 6, 2021 | $1K–15K | Jun 23, 2021 48 days late |
| Tom Malinowski NJ07 | Bought | Apr 20, 2021 | $1K–15K | Jun 12, 2021 53 days late |
| Tom Malinowski NJ07 | Bought | Jan 15, 2021 | $1K–15K | Mar 5, 2021 49 days late |
| Tom Malinowski NJ07 | Bought | Nov 2, 2020 | $1K–15K | Mar 5, 2021 123 days late |
| Tom Malinowski NJ07 | Bought | Sep 26, 2019 | $15K | Mar 5, 2021 526 days late |
| Tom Malinowski NJ07 | Bought | Aug 23, 2019 | $1K–15K | Mar 5, 2021 560 days late |
| Tom Malinowski NJ07 | Bought | May 31, 2019 | $15K | Mar 5, 2021 644 days late |
| Tom Malinowski NJ07 | Bought | May 30, 2019 | $15K | Mar 5, 2021 645 days late |
See a number that looks wrong?